Wall Street brokerages expect AxoGen, Inc. (NASDAQ:AXGN) to post $14.40 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for AxoGen’s earnings, with estimates ranging from $14.22 million to $14.57 million. AxoGen posted sales of $10.38 million in the same quarter last year, which would indicate a positive year over year growth rate of 38.7%. The company is expected to report its next earnings report after the market closes on Wednesday, August 2nd.

According to Zacks, analysts expect that AxoGen will report full year sales of $14.40 million for the current year, with estimates ranging from $58.36 million to $58.42 million. For the next financial year, analysts expect that the firm will report sales of $80.27 million per share, with estimates ranging from $79.37 million to $81.17 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover AxoGen.

AxoGen (NASDAQ:AXGN) last issued its earnings results on Thursday, May 4th. The medical equipment provider reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by $0.01. The company had revenue of $12.24 million during the quarter, compared to the consensus estimate of $11.83 million. AxoGen had a negative return on equity of 155.78% and a negative net margin of 32.05%.

A number of equities research analysts have weighed in on the stock. Wedbush reiterated an “outperform” rating and set a $14.00 price target (down from $17.00) on shares of AxoGen in a research report on Friday, May 19th. Cantor Fitzgerald assumed coverage on shares of AxoGen in a research report on Thursday, June 29th. They set an “overweight” rating and a $18.00 price target for the company. Finally, ValuEngine upgraded shares of AxoGen from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $14.38.

AxoGen (AXGN) opened at 16.95 on Friday. AxoGen has a 52 week low of $6.41 and a 52 week high of $17.25. The company’s market capitalization is $560.96 million. The firm has a 50-day moving average of $15.67 and a 200-day moving average of $12.29.

WARNING: “Zacks: Brokerages Anticipate AxoGen, Inc. (NASDAQ:AXGN) Will Post Quarterly Sales of $14.40 Million” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/22/zacks-brokerages-anticipate-axogen-inc-nasdaqaxgn-will-post-quarterly-sales-of-14-40-million.html.

Large investors have recently made changes to their positions in the stock. Parametric Portfolio Associates LLC boosted its stake in shares of AxoGen by 0.9% in the first quarter. Parametric Portfolio Associates LLC now owns 10,843 shares of the medical equipment provider’s stock worth $113,000 after buying an additional 93 shares in the last quarter. Campbell & CO Investment Adviser LLC boosted its stake in shares of AxoGen by 3.2% in the first quarter. Campbell & CO Investment Adviser LLC now owns 11,055 shares of the medical equipment provider’s stock worth $116,000 after buying an additional 341 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of AxoGen by 8.7% in the first quarter. Bank of America Corp DE now owns 10,183 shares of the medical equipment provider’s stock worth $106,000 after buying an additional 814 shares in the last quarter. American International Group Inc. boosted its stake in shares of AxoGen by 7.7% in the first quarter. American International Group Inc. now owns 14,941 shares of the medical equipment provider’s stock worth $156,000 after buying an additional 1,068 shares in the last quarter. Finally, UBS Group AG boosted its stake in shares of AxoGen by 8.3% in the first quarter. UBS Group AG now owns 16,141 shares of the medical equipment provider’s stock worth $169,000 after buying an additional 1,234 shares in the last quarter. Institutional investors and hedge funds own 63.73% of the company’s stock.

Get a free copy of the Zacks research report on AxoGen (AXGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.